CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immunotherapy company specializing in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. The companyâs flagship product, CytoSorbÂŽ, is approved in the European Union with distribution in 55 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the âcytokine stormâ or âcytokine release syndromeâ that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death and cost of treatment are extremely high, yet no effective treatments exist. CytoSorbÂŽ is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, that can lead to post-operative complications, including multiple organ failure. CytoSorbÂŽ has been used safely in more than 56,000 human treatments to date.
CytoSorbentsâ blood purification technologies are based on advanced, biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead, approximately the size of a grain of salt, contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies from blood. These beads are synthesized at CytoSorbentsâ ISO 13485 certified manufacturing facility in New Jersey. A companion product for the animal health market that uses similar technology to CytoSorbÂŽ, called VetResQÂŽ , is now commercially available in the United States. In addition, HemoDefendâ˘, a packed red cell transfusion filter designed to improve the safety and quality of transfused blood, is nearing human pivotal studies in the U.S. in the second half of 2019 that are intended to support U.S. FDA approval. The Company has numerous other products under development based upon this unique blood purification technology, protected by 19 issued U.S. patents and multiple applications pending, including CytoSorb-XL, K+ontrol, ContrastSorb, DrugSorb, and others.
Source
